Mónica Sierra Ausín
A5008922626- Inflammatory Bowel Disease
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Gastric Cancer Management and Outcomes
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Tumor Research and Treatment
- Gastrointestinal disorders and treatments
- Intraperitoneal and Appendiceal Malignancies
- Autoimmune Bullous Skin Diseases
- Lymphoma Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Biosimilars and Bioanalytical Methods
- Mycobacterium research and diagnosis
- Intestinal Malrotation and Obstruction Disorders
- Liver Diseases and Immunity
- Hypertrophic osteoarthropathy and related conditions
- Pericarditis and Cardiac Tamponade
- Colorectal Cancer Screening and Detection
- Clostridium difficile and Clostridium perfringens research
- Pregnancy and Medication Impact
- Retinal and Optic Conditions
- Anorectal Disease Treatments and Outcomes
- Vasculitis and related conditions
- Colorectal and Anal Carcinomas
Complejo Asistencial Universitario de Palencia
2012-2025
Hospital de León
2008-2025
Abstract Background 30% of patients with ulcerative colitis (UC) develop an acute severe (ASUC), which involves risk colectomy and has limited treatments despite the development new drugs. ASUC do not respond to steroids 25% are refractory cyclosporine or infliximab (IFX) precise colectomy. High-dose tofacitinib recent case series upadacitinib have demonstrated effectiveness in these scenarios1. Methods Retrospective, descriptive unicentric study 9 admitted hospital steroid-refractory ASUC....
Despite having adopted preventive measures, tuberculosis (TB) may still occur in patients with inflammatory bowel disease (IBD) treated anti-tumour necrosis factor (anti-TNF). Data on the causes and characteristics of TB cases this scenario are lacking. Our aim was to describe anti-TNF-treated IBD after publication Spanish prevention guidelines evaluate safety restarting anti-TNF a diagnosis.In multicentre, retrospective, descriptive study, from hospitals were collected. Continuous variables...
Abstract Background Inflammatory bowel disease (IBD) is a chronic and systemic that worsens quality of life, even in patients remission. Half those diagnosed have fatigue third anxiety. Reducing disability one goals treatment, included the STRIDE-II document. However, measuring daily practice can be challenging. The IBD-disk visual tool with short, self-administered questions used to improve communication patient, as it assesses different areas which we are not usually explored during...
Background: Pediatric-onset familial inflammatory bowel disease (IBD) may differ from sporadic pediatric-onset IBD in its genetic and environmental background have distinct clinical therapeutic implications. Objective: To evaluate the influence of a positive family history on use medical therapies surgical interventions adult patients with IBD. Methods: Retrospective case–control study using Spanish ENEIDA registry, including adults diagnosed since 2006. Familial forms (FFs) (defined by...
Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between CD location therapeutic patterns.
Markers that allow for the selection of tailored treatments individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was describe trends in real-life treatment usage. For this purpose, from ENEIDA registry who received their first targeted IBD (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis Machine Learning models performed. The study included 10,009 [71% Crohn’s disease (CD) 29% ulcerative colitis (UC)]. In CD,...
Abstract Background and aims Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of familial IBD on use medical surgical treatments biological era. Methods Patients included prospectively maintained ENEIDA database diagnosed with after 2005 were included. forms defined as those cases at least one first-degree relative Disease phenotype, agents, or main outcomes. Results A total 5263 patients [2627 Crohn’s (CD); 2636...
We present the case of a 64-year-old male diagnosed with corticosteroid-dependent ulcerative colitis in 1999, who underwent total proctocolectomy J-pouch 2005. Three years later, he developed recurrent histologically confirmed pouchitis, clinical worsening. Several therapies were tried, including Infliximab, which provided stability for six years, until development antibodies led to moderate pouchitis rectal stump. Attempts Adalimumab, Vedolizumab, and Ustekinumab failed, leading worsening...
Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess persistence, effectiveness, and safety in a real-world scenario.
An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims our study were to determine the clinical presentation, previous exposure immunosuppressive and biologic therapies, evolution lymphomas IBD. IBD diagnosis from October 2006 June 2021 identified prospectively maintained ENEIDA registry GETECCU. We 52 (2.4 cases lymphoma/1000 IBD; 95% CI 1.8–3.1). Thirty-five men (67%), 52% had ulcerative colitis, 60% received thiopurines, 38% an...
Abstract Background The use of ustekinumab (UST) and vedolizumab (VDZ) as first line therapy for inflammatory bowel disease (IBD) is increasing due to safety reasons contraindications anti-TNFs. However, there are no studies evaluating their efficacy in clinical practice under these circumstances. Thus, our aims were describe bionaïve patients’ characteristics starting VDZ or UST evaluate treatment persistence drugs profile this scenario. Methods Descriptive, retrospective multicenter study...
Abstract Background and study aims Rates of new dysplastic lesions or cancer progression after first dye chromoendoscopy in the era high-definition endoscopy have yet to be determined. Patients methods A multicenter, population-based, retrospective cohort was performed seven hospitals Spain. with inflammatory bowel disease fully resected (R0) colon under surveillance dye-based were sequentially enrolled between February 2011 June 2017, a minimum endoscopic follow-up 36 months. The aim assess...
Abstract Background After antiTNF failure, a second in Crohn's disease (CD) is effective to achieve and maintain remission, but only50% remain with the drug after 12 months of treatment. Ustekinumab (UST) has better persistence as second-line treatment induce long-term remission. Methods Retrospective observational study retrieved from prospective database patients treated UST, approval Research Ethics Committee. Data were collected at beginning 4, 8, 16, 24 weeks, 12, 24, 36, 48, 60 end...
Abstract Background Crohn's disease (CD) presents differences in genetics, inflammatory components, and microbiota depending on its location. Therapy efficacy may be linked to location, but existing research has yielded conflicting results. This study aims investigate the impact of CD location first-line biologic therapy requirement persistence risk intestinal resections. Methods patients included prospectively maintained ENEIDA registry between January 2005 May 2023 were considered for...
Protein-losing enteropathy is a relatively uncommon syndrome characterized by excessive loss of proteins into the intestinal lumen. It can be caused various etiologies. Inflammatory bowel disease (IBD) first condition we think when meet patient with ulcers and hypoproteinemia. However, there are many other complicated novel etiologies, which must aware in order to perform an appropriate differential diagnosis, such as one present.